CA2609549A1 - Treatment of eye disorders with sirtuin modulators - Google Patents

Treatment of eye disorders with sirtuin modulators Download PDF

Info

Publication number
CA2609549A1
CA2609549A1 CA002609549A CA2609549A CA2609549A1 CA 2609549 A1 CA2609549 A1 CA 2609549A1 CA 002609549 A CA002609549 A CA 002609549A CA 2609549 A CA2609549 A CA 2609549A CA 2609549 A1 CA2609549 A1 CA 2609549A1
Authority
CA
Canada
Prior art keywords
compound
formula
attendant definitions
sirtuin
further embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002609549A
Other languages
English (en)
French (fr)
Inventor
Michael Milburn
Christoph H. Westphal
David J. Livingston
Philip Lambert
Karl D. Normington
Peter Elliott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtris Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2609549A1 publication Critical patent/CA2609549A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002609549A 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators Abandoned CA2609549A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68425205P 2005-05-25 2005-05-25
US60/684,252 2005-05-25
US73155005P 2005-10-28 2005-10-28
US60/731,550 2005-10-28
US78835806P 2006-03-30 2006-03-30
US60/788,358 2006-03-30
PCT/US2006/020406 WO2006127987A2 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators

Publications (1)

Publication Number Publication Date
CA2609549A1 true CA2609549A1 (en) 2006-11-30

Family

ID=37307152

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002609549A Abandoned CA2609549A1 (en) 2005-05-25 2006-05-24 Treatment of eye disorders with sirtuin modulators

Country Status (5)

Country Link
EP (1) EP1928440A2 (https=)
JP (1) JP2008542296A (https=)
AU (1) AU2006249816A1 (https=)
CA (1) CA2609549A1 (https=)
WO (1) WO2006127987A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
WO2009089011A2 (en) * 2008-01-08 2009-07-16 Sirtris Pharmaceuticals, Inc. Resveratrol formulations
ES2586459T3 (es) 2008-05-01 2016-10-14 Glaxosmithkline Llc Quinolinas y análogos relacionados como moduladores de sirtuina
CA2729128C (en) 2008-07-03 2016-05-31 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
MX2011003373A (es) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Quinazolinona, quinolona y analogos relacionados como moduladores de sirtuina.
WO2010089104A2 (en) * 2009-02-04 2010-08-12 Dsm Ip Assets B.V. Resveratrol compositions
GB0903688D0 (en) * 2009-03-03 2009-04-15 Agentis Suppliments Composition
MX2012004995A (es) 2009-10-29 2012-10-03 Sirtris Pharmaceuticals Inc Piridinas biciclicas y analogos como moduladores de sirtuina.
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
WO2013033513A1 (en) 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
JP6356614B2 (ja) 2012-02-17 2018-07-11 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 薬剤のミトコンドリア輸送のためのナノ粒子
NZ700182A (en) 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
JP5955750B2 (ja) * 2012-11-20 2016-07-20 株式会社東洋新薬 皮膚外用剤
EP2968306B1 (en) 2013-03-15 2023-06-07 Washington University Administration of nicotinamide mononucleotide in the treatment of dry eye
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US20160374918A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Encapsulated skin care agent
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
WO2017004101A1 (en) * 2015-06-29 2017-01-05 The Procter & Gamble Company Skin care compositions comprising particles with nicotinamide riboside and methods of using the same
KR102114892B1 (ko) 2016-01-11 2020-05-26 더 프록터 앤드 갬블 캄파니 피부 상태의 치료 방법 및 그를 위한 조성물
KR102622656B1 (ko) 2016-02-18 2024-01-10 인버사, 인크. 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법
JP7090336B2 (ja) * 2016-08-08 2022-06-24 慶應義塾 Ｎａｄ関連代謝産物の利用
WO2018052019A1 (ja) * 2016-09-13 2018-03-22 めぐみ 田中 視覚機能改善剤及び視覚機能の改善方法
WO2018089797A1 (en) * 2016-11-14 2018-05-17 Mingwu Wang Formulations for the treatment of ocular surface diseases and related methods
US20210137961A1 (en) * 2017-03-07 2021-05-13 Cempra Pharmaceuticals, Inc. Compositions and Methods for Treating Dry Eye Diseases
WO2018237218A1 (en) 2017-06-23 2018-12-27 The Procter & Gamble Company COMPOSITION AND METHOD FOR ENHANCING SKIN APPEARANCE
US10946034B2 (en) 2018-03-27 2021-03-16 Invirsa, Inc. Methods for the use of 5′-adenosine diphosphate ribose (ADPR)
KR20210011964A (ko) 2018-07-03 2021-02-02 더 프록터 앤드 갬블 캄파니 피부 병태를 치료하는 방법
CN114007693B (zh) * 2019-06-25 2024-07-12 千寿制药株式会社 烟酰胺单核苷酸(nmn)及烟酰胺核苷(nr)的新用途
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
CN115843238B (zh) 2020-06-01 2025-06-10 宝洁公司 改善维生素b3化合物渗透到皮肤中的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
KR900700114A (ko) * 1988-01-19 1990-08-11 모세 쥬다 포크만 성장억제 작용제 및 그 사용법
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
AU1853000A (en) * 1998-12-24 2000-07-31 1333366 Ontario Inc. A composition useful to treat periodontal disease
JP2000344622A (ja) * 1999-03-31 2000-12-12 Sunstar Inc スチルベン系化合物及びそれを含有する植物抽出物の安定化およびスチルベン系化合物及びそれを含有する植物抽出物を安定配合した食品、医薬品、化粧品、口腔製剤
CA2312505A1 (en) * 2000-06-27 2001-12-27 1333366 Ontario Inc. Resveratrol compositions for topical use in the treatment of oral diseases and infections
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
ES2190771B2 (es) * 2002-01-24 2004-03-01 Univ Alicante Procedimiento para la produccion de resveratrol en cultivos celulares.
JP2003252760A (ja) * 2002-03-01 2003-09-10 Mitsubishi Pharma Corp 網膜疾患治療剤および／または予防剤
CN1220486C (zh) * 2002-11-15 2005-09-28 董英杰 白藜芦醇类化合物的β－环糊精或其衍生物的包合物及其制备方法
EP1621199B8 (en) * 2003-04-18 2011-01-19 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
JP2007530417A (ja) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
JP2007509035A (ja) * 2003-10-10 2007-04-12 レスバーロジックス コーポレイション Ｅｇｒ−１エンハンサー要素に関連する疾患の処置
DE102004002787A1 (de) * 2004-01-19 2005-08-11 Merck Patent Gmbh Flavonoid-Komplexe
CN1964627B (zh) * 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
EP1850840A2 (en) * 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators

Also Published As

Publication number Publication date
JP2008542296A (ja) 2008-11-27
AU2006249816A1 (en) 2006-11-30
EP1928440A2 (en) 2008-06-11
WO2006127987A2 (en) 2006-11-30
WO2006127987A3 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
AU2006230478B2 (en) Treatment of eye disorders with sirtuin modulators
CA2609549A1 (en) Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) Treatment of eye disorders with sirtuin modulators
KR102525438B1 (ko) 안과용 활성 약학 성분 전달을 위한 고형 사이클로덱스트린 복합체의 제조
CN107708664B (zh) 酪胺酸激酶抑制剂的眼用调配物、其使用方法、及其制备方法
EP2600850B1 (en) Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
US9925149B2 (en) Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
CA2537820C (en) Process for preparing water-soluble medicaments comprising complexation of forskolin in cyclodextrins
JP2025087858A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
KR20060127043A (ko) 녹내장성 망막병증 및 시각신경병증의 치료용 약제
JP2020073564A (ja) インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
KR20170097601A (ko) 생물활성, 나노입자포집된 항산화제의 운반
Shree et al. Applications of nanotechnology-mediated herbal nanosystems for ophthalmic drug
CN118891032A (zh) 用于延长释放非诺贝特的微球
US20180263954A1 (en) Sustained Release Cannabinoid Formulations
US11318090B1 (en) In situ gelling composition as a pH-selective and mucoadhesive sustained release drug delivery system
US11285148B1 (en) Ketoconazole ophthalmic preparations containing trans-ethosomal drug nanoparticles
CA3044636A1 (en) Lipid formulations of carmustine
KR101771483B1 (ko) 루테인의 용출률 및 안정성이 개선된 이중층 구조의 고분자 캡슐, 이의 제조방법 및 이를 함유하는 안과질환 예방 또는 치료용 약제학적 조성물
Cetin A review on ophthalmic delivery systems containing flavonoids for the treatment of eye diseases
JP6502393B2 (ja) ニコチンと酸化セリウムとのナノ粒子複合体及びその使用
Khin Development of fenofibrate/cyclodextrin complex loaded eudragit nanoparticles for ocular delivery
KUMAR et al. NANOTECHNOLOGY-DRIVEN THERAPEUTICS: ENHANCING BRAIN DRUG DELIVERY VIA NASAL PATHWAYS
Ghosal et al. Pelagia Research Library
HK1098450B (en) Process for preparing water soluble diterpenes and their applications

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140328